Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

SOUTH SAN FRANCISCO, Calif., April 11, 2007 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today provided a clinical update on R788, which is currently in ongoing Phase 2 clinical trials in immune thrombocytopenic purpura (ITP), rheumatoid arthritis (RA) and lymphoma patients. R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage.

Rigel commenced an exploratory Phase 2 clinical trial of R788 in January 2007 to evaluate its safety and efficacy in chronic ITP patients. In this clinical trial, R788 was orally administered in doses ranging from 75mg BID to 125mg BID for 30 or more days. We have observed encouraging preliminary drug activity in raising platelet counts in a number of the patients studied to date. Based on these initial results, we have submitted an amended protocol to the FDA to expand this trial to allow for a greater range of dose regimens and to continue to treat those patients that are responding beyond 90 days. We expect to receive final results from the study by the end of 2007.

"We are enthusiastic about these preliminary observations in raising platelet counts in most of the patients studied to date, without discernible issues of safety and tolerability" said James B. Bussel, M.D., Director of the Platelet Disorder Center, Children's Cancer and Blood Foundation Division at the New-York-Presbyterian Hospital/Weill Cornell Medical Center, New York.

In September 2006, Rigel commenced a Phase 2, multi-center, ascending dose, randomized, double-blind, placebo-controlled, dose ranging clinical trial to evaluate up to three doses of R788 in RA patients, on methotrexate, for 90 days. Rigel has completed the first dose group (50mg BID) in the clinical trial and is currently enrolling patients in the second dose group (100mg BID). To date, R788 appears to be
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... LAWRENCE, Mass., Nov. 9, 2010 NxStage Medical, ... manufacturer of innovative dialysis products, today announced that ... Brown, Chief Financial Officer, will participate in the ... Healthcare Summit Boston Harbor Hotel Boston, MATuesday, November ...
... ATLANTA, Nov. 9, 2010 The addition of ... associated with a rapid clinical response, improved function ... of adult rheumatoid arthritis (RA) patients reflecting those ... prior TNF-inhibitor use).  These positive clinical trial data ...
Cached Medicine Technology:NxStage Announces Fourth Quarter 2010 Investor Conference Schedule 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... and distributor of patented products, launches the Big Little ... ability to customize the perfect table that will suit ... reached a whopping revenue of $646 billion this past ... billion a year industry" says Scott J. Cooper, CEO ...
(Date:5/25/2015)... HomeCare is proud to announce that David Allerby, Co-Founder ... Iwamoto, Co-Founder & CMO, are Finalists for the Ernst ... Greater Los Angeles. The award is presented by EY ... and a personal commitment to their communities. , “Our ... of our organization,” said Co-Founder & CEO, David Allerby, ...
(Date:5/25/2015)... MA (PRWEB) May 25, 2015 A recent ... 2015 states 1,000 persons have died as a direct result ... 2014. This marks a 33% rise in overdose deaths attributed ... Charlie Baker, “This issue doesn’t care about geography. This issue ... This issue doesn’t care about class.” As the state of ...
(Date:5/25/2015)... May 25, 2015 Thousands of ... move forward in the federal multidistrict litigation now ... Texas. According to a Motion filed on May ... modify the Case Management Order pertaining to the ... things, the Motion seeks the adoption of a ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 Join Fiona's ... a free two-hour instructional clinic. Irish National Player, Fiona ... and give them a taste of her coaching style. Fiona ... and Novato. Camps in Novato are at Lynwood Elmentary School ... , Novato High School - June 6th, 2015 - 1:00-3:00pm. ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2
... and even old socks litter the shores of Lau Fau ... of the territory's oyster farming industry. From across the ... over Deep Bay, one of Hong Kong's most polluted stretches ... handed back to the Chinese, pollution is one of the ...
... having mood swings, and stays out late, then it could very ... ,The finding is based on a new research by ... on 107 adolescents with an average age of 17.98 years. ... were in love, and were experiencing intense romantic love, while the ...
... that around 350, 000 British senior citizens ... . , The major survey carried out by the ... by the Department of Health and Comic Relief is the first ... report titled: UK Study of Abuse and Neglect, found that 4 ...
... Schwarzenegger will call on British Prime Minister Tony Blair ... ,The California Governor wanted to work with ... warming, said a source close to Blair. ... speeches for when Mr Blair retires on June 27, ...
... Researchers at the University of Illinois at Chicago and ... silenced genes in patients who suffer from Neurodegenerative diseases ... stroke, certain cellular events take place that lead to ... group of enzymes called histone deacetylases can modulate gene ...
... restricted only to difficulty in walking on a uneven stretch, ... high heels are also making driving dangerous for over 12 ... footwear for driving and said that women are actually risking ... conducted by women's car insurance concern Sheilas Wheels revealed that ...
Cached Medicine News:Health News:Hong Kong Choked by Growing Pollution Problem 2Health News:Hong Kong Choked by Growing Pollution Problem 3Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
Inquire...
Inquire...
Inquire...
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Medicine Products: